• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Immuno-Gene Therapy for the Oral Squamous Cell Carcinoma using with Anti-Tumor Cytotoxic T-Lymphocytes.

Research Project

Project/Area Number 08457541
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Surgical dentistry
Research InstitutionTokyo Medical and Dental University

Principal Investigator

TAKAHASHI Yuzo  tokyo Medical and Dental University, Faculty of Detistry, The 2nd Department of Oral and Maxillofacial Surgery, Associate Professor., 歯学部, 助教授 (50014329)

Co-Investigator(Kenkyū-buntansha) 上田 晶義  東京医科歯科大学, 歯学部, 助手 (00272609)
鎌田 信之  東京医科歯科大学, 歯学部, 助手 (70242211)
Project Period (FY) 1996 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 1998: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1997: ¥1,400,000 (Direct Cost: ¥1,400,000)
KeywordsImmuno-Gene Therapy / MHC-restricted anti-tumor cytotoxic T-lymhocytes / Oral squamous cell carcinoma / CD80-modified human tumor cells / 特異的免疫療法 / 腫瘍重度遺伝子治療 / 口腔扁平上皮癌 / 腫瘍免疫遺伝子治療 / 腫瘍特異的細胞障害性Tリンパ球(CTL) / CD80 / IL-12
Research Abstract

Many trials for the generation of MHC-restricted anti-tumor cytotoxic T lymhocytes against squamous cell carcinoma of head and neck region including oral cavity, have been studied. However, it is usually difficult toachieve.
One of the reasons of this difficulty, is the lack of CD8O molecules on the surface of tumor cells. We induced the CD8O molecules into the tumor cells using adeno-vilus vectors. Efficient generation of anti-tumor cytotoxic T lymphocytes are generated with CD8O-modified human tumor cells and IL-12. However, the sufficient number of effector cells for the patients therapy can not be generated.

Report

(4 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • 1996 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi